Bogle Investment Management’s Emergent Biosolutions EBS Stock Holding History

Bogle Investment Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,731	Closed	-$334K	–	37
2020 Q4	$334K	Sell	3,731 -11,363	-75%	-$1.04M	0.53%	103
2020 Q3	$1.56M	Buy	15,094 +494	+3%	+$53.3K	0.46%	95
2020 Q2	$1.16M	Buy	+14,600	New	+$1.09M	0.19%	157
2018 Q3	–	Sell	-82,616	Closed	-$4.17M	–	284
2018 Q2	$4.17M	Sell	82,616 -54,022	-40%	-$2.81M	0.3%	108
2018 Q1	$7.19M	Buy	+136,638	New	+$6.81M	0.54%	76
2017 Q2	–	Sell	-39,951	Closed	-$1.16M	–	320
2017 Q1	$1.16M	Buy	+39,951	New	+$1.22M	0.08%	210
2016 Q4	–	Sell	-162,870	Closed	-$5.13M	–	347
2016 Q3	$5.13M	Sell	162,870 -124,896	-43%	-$3.63M	0.37%	94
2016 Q2	$8.09M	Buy	+287,766	New	+$11.3M	0.56%	66
2016 Q1	–	Sell	-49,842	Closed	-$1.99M	–	402
2015 Q4	$1.99M	Buy	+49,842	New	+$1.74M	0.14%	189
2014 Q2	–	Sell	-193,383	Closed	-$4.89M	–	345
2014 Q1	$4.89M	Buy	+193,383	New	+$4.88M	0.34%	106

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bogle Investment Management's EBS Position: Q1 2021 in Review

Bogle Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 3,731 shares — an estimated $334K sold.

Bogle Investment Management first reported a position in EBS in Q1 2014 and held it in 10 quarters. The position peaked at $8.09M in Q2 2016. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

Bogle Investment Management reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
Bogle Investment Management sold 3,731 Emergent Biosolutions shares in Q1 2021, an estimated $334K.
Bogle Investment Management first reported a position in Emergent Biosolutions in Q1 2014 and held it in 10 quarters.
Bogle Investment Management's Emergent Biosolutions position peaked at $8.09M in Q2 2016.
340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.